159 related articles for article (PubMed ID: 22534502)
1. Finasteride attenuates pathological gambling in patients with Parkinson disease.
Bortolato M; Cannas A; Solla P; Bini V; Puligheddu M; Marrosu F
J Clin Psychopharmacol; 2012 Jun; 32(3):424-5. PubMed ID: 22534502
[No Abstract] [Full Text] [Related]
2. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
Gerschlager W; Bloem BR
Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
[No Abstract] [Full Text] [Related]
3. Dopamine dysregulation syndrome including mania related to coadministration of droxidopa.
Saito S; Shioda K; Nishijima K
J Clin Psychopharmacol; 2012 Jun; 32(3):428-9. PubMed ID: 22561478
[No Abstract] [Full Text] [Related]
4. Clozapine for medication-related pathological gambling in Parkinson disease.
Rotondo A; Bosco D; Plastino M; Consoli A; Bosco F
Mov Disord; 2010 Sep; 25(12):1994-5. PubMed ID: 20669252
[No Abstract] [Full Text] [Related]
5. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
6. Drugs for treating Parkinson disease.
Belavic J
Nursing; 2012 Jul; 42(7):69. PubMed ID: 22739529
[No Abstract] [Full Text] [Related]
7. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
8. Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Ahlskog JE
Mayo Clin Proc; 2014 Jul; 89(7):997-1003. PubMed ID: 24996235
[TBL] [Abstract][Full Text] [Related]
9. Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.
Sampaio C; Ferreira JJ
Nat Rev Neurol; 2010 Nov; 6(11):590-1. PubMed ID: 21048799
[No Abstract] [Full Text] [Related]
10. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
11. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
[TBL] [Abstract][Full Text] [Related]
12. [Long term experience with Stalevo in Szeged, Hungary].
Klivényi P; Vécsei L
Ideggyogy Sz; 2009 May; 62(5-6):178-80. PubMed ID: 19579666
[TBL] [Abstract][Full Text] [Related]
13. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
14. Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
Pouclet H; Derkinderen P; Lebouvier T
Clin Neurol Neurosurg; 2013 Feb; 115(2):235-6. PubMed ID: 22743235
[No Abstract] [Full Text] [Related]
15. Is pathological gambling in Parkinson's disease reduced by amantadine?
Lee JY; Kim HJ; Jeon BS
Ann Neurol; 2011 Jan; 69(1):213-4; author reply 214-5. PubMed ID: 21280095
[No Abstract] [Full Text] [Related]
16. [Pathological gambling associated with pramipexole use in Parkinson's disease].
Lester J; Gonzalez-Aleman G; Zuniga-Ramirez C; Diaz-Pascuali SP; Raina-Castellino GB; Micheli-Gould F
Rev Neurol; 2006 Sep 1-15; 43(5):316-8. PubMed ID: 16941434
[No Abstract] [Full Text] [Related]
17. [Pathologic gambling as an adverse effect of the treatment for Parkinson's disease].
Miranda M; Slachevsky A; Bustamante L; Pérez C
Rev Med Chil; 2010 Apr; 138(4):521-2. PubMed ID: 20668805
[No Abstract] [Full Text] [Related]
18. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
[TBL] [Abstract][Full Text] [Related]
19. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.
Manca D; Cossu G; Murgia D; Molari A; Ferrigno P; Marcia E; Melis M
Mov Disord; 2009 Nov; 24(15):2293-4. PubMed ID: 19795477
[No Abstract] [Full Text] [Related]
20. Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
Parkinsonism Relat Disord; 2009 Jul; 15(6):477-8. PubMed ID: 19028438
[No Abstract] [Full Text] [Related]
[Next] [New Search]
